Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "novel transcript, antisense to MRPS18A" likely refers to a predicted or experimentally observed non-coding RNA transcript oriented antisense to the MRPS18A gene. MRPS18A encodes mitochondrial ribosomal protein S18A, which is involved in mitochondrial protein synthesis as a component of the small 28S ribosomal subunit. The antisense transcript does not correspond to a characterized protein-coding gene and is not widely recognized or annotated in genomic databases, nor is there known biological or therapeutic significance attached to it. The Ensembl identifier "ENSG00000310441" is not a recognized Ensembl identifier for any gene or transcript, suggesting a possible misspelling, an outdated identifier, or a misannotation. The canonical gene, MRPS18A, is a structural constituent of mitochondrial ribosomes but is not known as a common drug target or biomarker. This antisense transcript is not a validated drug target, molecular family member, or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to MRPS18A.